Virginia Commonwealth University

The United States Government as Represented by the Department of Veterans Affairs

Mcguire Va Medical Center 111K

Paul Dent

Paul B Fisher

Devanand Sarkar

Steven Grant

Chunrong Yu

W David Jarvis

Geoffrey Krystal

A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7)

Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Ablleukemia resistant to compound of formula I.

Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer

Mammaliam cancer cells are effectively killed when treated with a lethal agent (e.g. radiation or chemotherapeutic agents) in combination with an inhibitor specific for the p42/44 MAP kinase cascade 'proper'.

Specific inhibition of the P42/44 mitogen activated protein (map) kinase

Growing community of inventors

Richmond, VA, United States of America

Paul Dent